Search
English
中文
About Us
At a Glance
History and Milestones
Global Recognition
Management Team
Research & Development
Oncology
Autoimmune Diseases
Facility and Capacity
Products
Pipeline Overview
HMPL-004
HMPL-011
Sulfatinib
Fruquintinib
HMPL-813
Collaborations
Collaboration Overview
Existing Partnerships
Media
Key Facts
Press Releases
Featured Articles
Careers
Contacts
Press Releases
12/21/2011
AstraZeneca and Hutchison Medi Pharma Enter into Global Collaboration to Co-Develop and Commercialize Novel Cancer Therapy
11/08/2011
Hutchison Medi Pharma initiates Phase I clinical study for its novel EGFR inhibitor Epitinib
09/20/2011
Director Liu Yugeng comes for an inspection of strategic development of new industries
08/04/2011
The Wall Street Journal Asia’s Asian Innovation Awards 2011 shortlist HMP
02/01/2011
Fruquintinib Receives SFDA IND Approval and Starts Phase I Clinical Trial for the Treatment of Cancer
12/21/2010
Hutchison MediPharma Receives Further Strategic Investment to Advance Its Pipeline
11/08/2010
Hutchison MediPharma Receives Strategic Investment to Advance Its Pipeline
10/18/2010
HMPL-004 Chosen as a Top 10 Inflammatory/Autoimmune Projects to Watch by Windhover and Healogix
10/18/2010
Hutchison MediPharma Wins Deloitte Fast 50 China Award
05/06/2010
Receives SFDA IND Approval and Begins Phase I Clinical Trial of Sulfatinib for the Treatment of Cancer
First Prev
Next
Last
Page：1/4 Record：33
Top
Back home
Print page
